Latest Breaking News On - Site reactions - Page 5 : comparemela.com

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo.1

United statesBin chenJohn cunninghamJun saitoCancer centerInternational blood marrow transplant researchHematopoietic cell transplant therapy programExchange commissionEuropean unionEuropean medicines agencyTakeda pharmaceutical company limitedMet its primary efficacy endpointClinically meaningful intestinalFree survivalNew safety signals were seenVedolizumab compared

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT No New. | February 18, 2023

United statesBin chenJohn cunninghamCancer centerInternational blood marrow transplant researchHematopoietic cell transplant therapy programExchange commissionEuropean unionEuropean medicines agencyTakeda pharmaceutical company limitedYi bin chenHematopoietic cell transplantCell therapy programMass general cancerSafety informationSpecial precautions

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acut

The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT (pNo New Safety Signals Were Seen with Vedolizumab Compared with Placebo in Patients Who Received Allo-HSCTData Were Presented as A La.

United statesBin chenJohn cunninghamJun saitoCancer centerInternational blood marrow transplant researchHematopoietic cell transplant therapy programExchange commissionEuropean unionEuropean medicines agencyTakeda pharmaceutical company limitedMet its primary efficacy endpointClinically meaningful intestinalFree survivalNew safety signals were seenVedolizumab compared

Alkermes plc: Alkermes Showcases Research from Psychiatry Portfolio at Psych Congress

? Clinical, Epidemiology and Health Economics and Outcomes Research Shared at Key Psychiatry Conference ? DUBLIN, Sept. 20, 2022 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced

United statesCraig hopkinsonMarisa borgasanoAripiprazole lauroxilSandy coombsPsych congressWellness survey dataResearch development at alkermesAnalysis of national healthOutcomes research shared at key psychiatry conferenceHealth economicsAlkermes incAlkermes pharma irelandOutcomes research sharedKey psychiatry conferenceChief medical officer

Novel Supportive Approach in Cancer Care Helps Protect Patients Bone Marrow from Chemotherapy Damage

Novel Supportive Approach in Cancer Care Helps Protect Patients Bone Marrow from Chemotherapy Damage
oncologynurseadvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from oncologynurseadvisor.com Daily Mail and Mail on Sunday newspapers.

Jared weissTammy allredDorothy turnerLineberger comprehensive cancer centerTherapeutics incInternational journal of cancerComprehensive cancerSite reactionsIncluding phlebitisSodium chloride injectionDextrose injectionBasu roy united kingdom